EnvoyHealth Selected by Sun Pharma to Support Imatinib Mesylate Patient Program
FLINT, Mich. – Feb. 22, 2016 – EnvoyHealth, a Diplomat company, will support a patient assistance call center program for Sun Pharma’s imatinib mesylate.
Diplomat Pharmacy, Inc. (NYSE: DPLO), announced today that EnvoyHealth, Diplomat’s own HUB solution provider, will support a patient assistance call center program for Sun Pharma’s imatinib mesylate.
This call center program will support patients with questions on the use of and access to Sun Pharma’s imatinib mesylate. The call center program intends to create swift patient access to affordable medication and to enhance therapy adherence. Imatinib mesylate is a kinase inhibitor used to treat adults and pediatric patients with Philadelphia + chronic myeloid leukemia (Ph+ CML) and other FDA approved indications. Sun Pharma’s imatinib mesylate is FDA approved as bioequivalent and therefore therapeutically equivalent to Gleevec® for the approved indications.
To learn more about EnvoyHealth, click here.
Services EnvoyHealth is offering to support the program include:
- Centralized call center support, featuring an educational program and copay card enrollment
- Patient assistance program
- 24/7/365 clinical helpline
“Through EnvoyHealth working collaboratively with Sun Pharma, we have created a solution that puts patients first,” said Diplomat CEO and Chairman Phil Hagerman. “This set of services will support patients with the education and services they need around imatinib mesylate use, to support them on their journey.”
EnvoyHealth collaboratively supports pharmaceutical manufacturers by designing programs specific to their specialty agent’s needs, supporting efficient medication access for specialty patients and managing complex therapies and costs. EnvoyHealth offers individualized patient-centric support, along with access solutions, inventory management, distribution and delivery, and other administrative support services.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
EnvoyHealth, a Diplomat company, helps patients live healthier longer lives, through flexible, firewalled HUB services, which include enrollment, benefits investigations, distribution processes and more. In 2014, Diplomat expanded its HUB services with EnvoyHealth Management, LLC, a wholly firewalled HUB subsidiary. EnvoyHealth provides patients the affordable, quality drug therapy they require by offering strategic support to the stakeholders who influence patient access to therapy and therapy adherence. For more information, visit www.envoyhealth.is.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
Cheryl Allen, RPh, BSPharm, MBA,
Vice President, Industry Relations
917.456.7189 | firstname.lastname@example.org
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO173 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…6 days ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm2 weeks ago